| Pharmaceutical Information |
| Drug Name |
Sulfinpyrazone |
| Drug ID |
BADD_D02094 |
| Description |
A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. |
| Indications and Usage |
For the treatment of gout and gouty arthritis. |
| Marketing Status |
approved |
| ATC Code |
M04AB02 |
| DrugBank ID |
DB01138
|
| KEGG ID |
D00449
|
| MeSH ID |
D013442
|
| PubChem ID |
5342
|
| TTD Drug ID |
D03DEI
|
| NDC Product Code |
Not Available |
| UNII |
V6OFU47K3W
|
| Synonyms |
Sulfinpyrazone | Sulphinpyrazone | Sulfoxyphenylpyrazolidin | Nu-Sulfinpyrazone | Nu Sulfinpyrazone | Anturane | Anturan | Apo-Sulfinpyrazone | Apo Sulfinpyrazone |
|
| Chemical Information |
| Molecular Formula |
C23H20N2O3S |
| CAS Registry Number |
57-96-5 |
| SMILES |
C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
